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Secretory immunoglobulin A (sIgA) is a primary factor
responsible for preventing attachment of enteropathogens
to gut epithelium in breastfeeding infants. We compared the
frequency of sIgA to major surface antigens of enterohem-
orrhagic  Escherichia coli (EHEC) in milk of 123 women
from the United States and Mexico to determine whether
regional differences existed in the frequency of antibodies
to these surface antigens. In both groups of women, milk
commonly has sIgA against various EHEC lipopolysaccha-
rides, EspA, EspB, intimin, and less frequently against
Shiga toxin. The study suggests that persons living in the
U.S. are exposed to attaching/effacing enteropathogens
more frequently than is generally assumed. The low fre-
quency of antibodies to Stx1 (in 12% of Mexican and in
22% of U.S. samples) suggests that the rare appearance of
hemolytic uremic syndrome in adults is not due to neutral-
ization of toxin at the gut level. Only anti-EspA is found in
most milk samples from both populations of women. EspA
may represent a useful target for an immunization strategy
to prevent EHEC disease in humans.
E
nterohemorrhagic Escherichia coli (EHEC) produces
multiple virulence factors; the most important are pro-
tein synthesis–inhibiting toxins: Shiga toxin 1 (Stx1) and 2
(Stx2). EHEC causes nonbloody diarrhea, hemorrhagic
colitis, and hemolytic uremic syndrome (HUS). A large
number of EHEC serotypes infect humans. In the United
States, the predominant EHEC serotype associated with
serious disease is E. coli O157:H7. HUS complicates
approximately 5% to 8% of infections caused by E. coli
O157:H7. 
Virulence in EHEC reflects not only toxin production
but also the pathogen’s ability to colonize the gut.
Colonization by EHEC is related to the pathogen’s ability
to form attaching and effacing lesions (intestinal mucosal
changes seen in transmission electron microscopy and
originally seen in intestines of animals infected with
enteropathogenic E. coli [EPEC]) (1). The lesions are char-
acterized by localized destruction of brush border
microvilli and intimate adhesion of the bacterium to the
host cell membrane. At the site of bacterial attachment, the
host cell membrane forms a pedestal-like structure.
Immunofluorescence microscopy has shown that the area
of host cell in proximity to the bacterium contains poly-
merized actin, α-actinin, talin, and ezrin (2). In both EHEC
and EPEC, the proteins that mediate this attachment are
encoded in a chromosomal pathogenicity island called the
“locus of enterocyte effacement” (LEE) (3). Secretion of
LEE proteins is triggered by close contact with host cells.
Once triggered to express LEE, the bacterium forms an
export apparatus that includes a tube made of multimers of
a protein (EspA); this surface organelle acts as a conduit
between the bacteria and host cell (4–6).  EspB, a protein
thought to be involved in pore formation, is transferred to
the host cell by this conduit and is found in both the host
cell membrane and cytosol (7). EspB, with the aid of a sec-
ond membrane lytic protein, EspD, forms pores in the host
cell as part of the translocation mechanism (8). The EspA
organelle is used to transfer the translocated intimin recep-
tor (Tir), which is then inserted into the host cell mem-
brane, where it binds to intimin, a bacterial outer mem-
brane protein (9,10) and triggers the host cytoskeletal
events that lead to attaching/effacing lesion formation. 
Development of specific immunity to these antigens
plays a role in protecting against infection. Immune
responses are elicited in patients who are infected with
EHEC or EPEC. Children infected with EPEC have been
shown to have serum immunoglobulin (Ig) G against
intimin, EspA, and EspB (11). Likewise, serum IgG
against Tir, intimin, EspA, and EspB has been demonstrat-
ed during EHEC infection (12–14). Specific IgG against
O157 lipopolysacchartide (LPS) (15) and against EHEC
intimin (16) blocks adherence in vitro. 
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pathogens. Because antibodies in milk reflect previous
immunologic events in the mother’s gut, human milk is
ideally suited for defining mucosal protective immunity.
Lymphocytes are known to travel from the gut to the mam-
mary gland. Human milk contains antibodies to EHEC
intimin, EspA, EspB, and Tir (17–20), and to EPEC
intimin (19). Incubation of colostrum or pooled human
milk decreases EPEC adherence (21–23). Hence, the pro-
tective effect seen in vitro has been attributed to the pres-
ence of these antibodies. The role of virulence
antigen–specific sIgA in protecting against EHEC has not
been assessed directly. For EHEC and EPEC, as for most
enteric pathogens, the best hope for disease control is
through a vaccine strategy. Candidates for an EHEC vac-
cine might, in theory, include the surface-exposed compo-
nents, secreted components, or both. 
Antibodies in human milk can be used as an epidemio-
logic tool because antibodies reflect previous infection in
the mother (24). We compared milk samples of women
from Mexico and from the United States for antibodies to
LPS and virulence proteins involved in the initial bacteria-
host cell interaction. We also evaluated milk samples for
antibodies to Stx1, a major secreted virulence factor of
EHEC. We compared the frequency and amount of anti-
bodies to each of the antigens in these two populations to
determine whether important differences in sIgA antibod-
ies exist that might provide insight into exposure to these
antigens and potential protective mechanisms. 
Methods
Population and Milk Collection 
Human milk samples were collected after informed
consent from 123 women living in two widely separated
areas of North America: Mexico City and Norfolk,
Virginia. None of the women had premature infants. The
study was approved by the Institutional Review Boards of
each participating institution. None of the women were
known to have an underlying illness. Whether they had
previously experienced infections with attaching/effacing
organisms was unknown. Milk samples were obtained by
using an Ameda Egnell pump (Hollister, Inc., Libertyville,
IL). Samples were stored at –70°C after collection. Human
milk samples were thawed and centrifuged at 13,200 rpm
three times to obtain a clear fraction. 
Preparation of Antigens
E. coli LPS
E. coli O157:H7 LPS was extracted with phenol water
by using the method described by Westphal and Jann (25).
Other purified LPS (O26, O55, O111, O127, and O128)
were obtained from Sigma (Aldrich Corp., St. Louis,
MO). 
Stx
Stx1 was purified from Shigella dysenteriae serotype 1
as previously described (26). We evaluated antibodies to
Stx1 rather than to Stx2 because approximately 90% of
EHEC produce Stx1. Stx2 appears to be less immunogenic
than is Stx1. 
EspA and EspB
E. coli M15 with the plasmids encoding either C termi-
nal histidine-tagged EspAor histidine-tagged EspB cloned
from EHEC E. coli O26:H- strain 413/89-1 (6)  was grown
in Terrific broth (ENE Mate, ISC Bioexpress; Kaysville,
UT) until optical density (OD) at A600 was 0.7. Bacteria
were induced by adding isopropyl-β-D-thiogalactopyra-
noside (IPTG) to a final concentration of 1 mM at 30°C for
3 h. For purifying EspB, phenylmethylsulfonyl fluoride (1
mM) was added to the culture media. The cells were har-
vested by centrifugation. The resulting pellet was lysed
through the addition of lysozyme and sonication. The
resulting supernatant was mixed with nickel nitriloacetic
agarose (Qiagen, Inc., Valencia, CA) for 1 h at 4°C. The
agarose was then poured into a column and washed with
increasing concentrations of imidazole in phosphate buffer
(10 mM) to elute the purified proteins. All steps during the
purification were performed under nondenaturing condi-
tions following manufacturer’s instructions. Sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) was performed to confirm purity of eluted proteins.
Intimin Gamma
The 281 amino acid C terminal (extracellular) portion
of intimin (C281γ) was cloned from E. coli O157:H7 strain
86-24 by using as forward primer 5-GATC- AAACCAAG-
GCCAGCATTACTGAGATT and reverse primer 5-
AATAATTATGCCC- CGACTAAAACA. The taq poly-
merase amplified segment was inserted into polymerase
chain reaction T7 NT-TOPO so that six histidine residues
were added to the N terminus. The sequence was verified
by digestion with EcoRI and BamHI and automated
sequencing by using dye-terminator chemistry (BigDye as
the fluorescent marker) in an ABI PRISM model 377
Genetic Analyzer (Applied Biosystems, Foster City, CA).
The plasmid was then inserted into BL21(DE3)pLysS and
expression inducted with IPTG. After partial purification
with nickel nitriloacetic agarose chromatography, the
amplified protein was detected on immunoblots (as
described below). The C281γ was located on SDS-PAGE
by size, intensity of the band after IPTC induction, and
confirmation that the band contained 6 x His by Western
blot.
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Immunosorbent Assay (ELISA) 
ELISA was used to determine the presence and amount
of sIgA against Stx1, EspA, EspB, and each LPS. The
amount of sIgAwas estimated based on the mean of dupli-
cate measures of OD of the antigen-coated wells minus the
control background wells. For each ELISA all samples
were run on the same day to eliminate day-to-day varia-
tion. For EspA, EspB, and each of the LPS, 96-well poly-
styrene plates were coated overnight at 4°C with 1 µg/well
of each antigen in carbonate buffer (pH 9.6). After coating,
plates were blocked with 200 µLof 5% bovine serum albu-
min (BSA) in 10 mM sodium phosphate-buffered saline
(PBS) for 1 h at 37°C. After each step, plates were washed
five times with PBS containing 0.05% Tween 80. Human
milk samples diluted 1:20 in 1% nonfat dry milk in PBS
were incubated at 37°Cfor 1 h. Goat anti-human sIgAcon-
jugated to horseradish peroxidase (Cappel Division of
Organon Teknika, Durham, NC) was added after washing.
Hydrogen peroxide with o-phenylenediamine dihy-
drochloride was used for color development. The reaction
was stopped by adding 2 N sulfuric acid, and plates were
read at 490 nm. For Stx1, we used a variation of a previ-
ously described receptor binding ELISA (27).  Polyvinyl
chloride plates were coated with Gb3, blocked with 5%
BSA-PBS, washed five times with PBS-Tween, and coat-
ed with 1 µg/well of toxin overnight at 4°C. The plates
were washed five times with PBS-Tween and blocked with
5% BSA-PBS before 100 µLof milk sample per well dilut-
ed 1:20 with 1% nonfat dry milk in PBS was applied. Goat
anti-human sIgAconjugated to horseradish peroxidase was
added after washing and OD determined as above.
SDS-PAGE and Western Blot Analysis 
SDS-PAGE was performed on the protein samples
diluted in sample buffer (2-mercapthoethanol, SDS, and
0.1% bromophenol blue), boiled for 5 min, and loaded into
12.5% gels. The protein bands were visualized by staining
with Coomassie blue. After SDS-PAGE, unstained protein
antigens or LPS were transferred electrophoretically onto
nitrocellulose membranes and blocked with 3% nonfat dry
milk in Tris buffer for 1 h. The membranes were incubat-
ed overnight with the human milk samples diluted 1:20
with 1% nonfat dry milk in Tris buffer at 4°C. After three
washes, the bound sIgA was detected by using peroxidase
conjugates as above with chloro-1-naphthol as the color
reagent. Western blot was used to determine the ELISA
sensitivity and specificity as well as to detect sIgAto C281γ. 
Statistical Analysis
Chi-square or Fisher exact test was used to compare the
frequency of sIgA-positive milk samples in the two popu-
lations for each antigen. Since anti-C281γ antibody was
detected by immunoblot rather than ELISA, its relation-
ship to other antibodies was determined by chi-square test
or Fishers exact test. For other antibodies that were meas-
ured quantitatively, differences between the populations in
amounts of antibodies were determined by a two-tailed
Mann-Whitney test. The correlation between the amount
of sIgA for different antigens was determined by linear
regression of ELISA ODs. Because of the multiple com-




Milk samples from 73 women in Mexico City and 50
women in Norfolk, Virginia, were studied. No difference
existed in the timing of collection of the milk samples
between the two populations (Table 1).  
Validation of Assays
Purification of histidine-tagged EspA and EspB result-
ed in a single band of protein in the eluate as visualized by
SDS-PAGE.  As expected, ELISAs were highly repro-
ducible. For example, the correlation between OD490 on
repeat assays of randomly chosen samples for antibody to
O111 was 0.858 (p<0.001), and for antibody to O26, the
correlation was 0.807 (p<0.001). Based on the Western
blot studies, the cutoff for a positive ELISA for each anti-
gen was considered to be an OD>0.1 at 490 nm. The sen-
sitivity and specificity of the ELISA for various antigens
were high as determined by using Western blot as the stan-
dard. For example, sensitivity and specificity were 82%
and 71% for O157 LPS, 100% and 88% for EspB, and
93% and 100% for EspA, respectively. Because of the
inherent differences in sensitivity of immunoblots com-
pared to enzyme immunoassays on plastic plates, by using
Western blot as the standard for defining ELISAcutoff, we
may have underestimated somewhat the frequency of milk
samples that contain sIgA to some antigens. 
Prevalence of Antibodies to EHEC Antigens 
Large variations occurred in frequencies of milk sam-
ples containing antibody to the various LPS.  The percent-
ages of milk samples that contained antibodies to various
LPS types were similar in the two populations, with the
exception of anti-O128, which occurred significantly more
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Table 1. Distribution of milk samples over duration of lactation in 
the two study cohorts 
No. days of lactation  Mexico (%)  United States (%) 
<5  16 (22)  11 (22) 
6–30  43 (59)  30 (60) 
>30  14 (19)  9 (18) 
Total  73 (100)  50 (100) often in milk samples from women from the United States
(Table 2). However, the amount of antibody to the various
LPSs differed significantly in the two settings. Mexican
women had higher levels of antibodies (Table 3) against
O55 and O127; they also had higher antibody levels
against EspA and EspB. Milk samples from U.S. women
had higher levels of antibodies against O26, O111, O128,
and Shiga toxin. 
Relationship of sIgA Antibodies to LSP, Intimin
Gamma, EspA, EspB, and Shiga Toxin 
Women in both populations who had antibodies to
EspB nearly always had antibodies to EspA in their milk;
98% of those whose milk samples were positive for anti-
EspB antibodies were also positive for anti-EspA antibod-
ies, whereas those who were positive for anti-EspA were
positive for anti-EspB 43% of the time (p<0.01 by chi
square). Although anti-EspB was found less often than
anti-EspA, the amount of anti-EspB correlated with the
amount of anti-EspA in both populations (Tables 4 and 5).
The amount of anti-EspA antibodies also was correlated
with anti-O55 in milk samples from Mexico and with anti-
O55 and anti-O127 milk samples from the United States.
The data regarding antibodies to antigens that are EHEC-
specific suggested that O55 and O111, but not O157, are
important EHEC serotypes in Mexico (Table 4) since anti-
Stx1 correlated well with antibodies to these LPS types.
These findings are consistent with studies of meat samples
in Mexico, which suggest that O157 is rarely found (28).
Anti-C281γ correlated with anti-Stx1 and anti-O55 in
Mexican women but not in U.S. women (Table 6). Most
milk samples (17 [85%] of 20) positive for anti-C281γ were
from Mexican women with antibody to O55 LPS
(p=0.0001). These relationships imply that Shiga toxin and
intimin gamma antibodies were linked to E. coli O55
infection. In the milk samples from U.S. women, anti-Stx
did not correlate with any LPS type including O157 (Table
5).  
Discussion
The specific antibodies that may be important in sIgA-
mediated passive immune protection and infection-
induced active immunity in human milk are not known.
Milk, because it contains the infection-triggered active
mucosal immune response of the mother, reflects antibod-
ies that are relevant to clearing her particular infection and
to subsequently protecting her infant. As such, milk anti-
bodies indicate to which antigens the immune system has
been most responsive. Focusing on such antigens may sug-
gest candidates for vaccine development. 
In EPEC, formation of the attaching/effacing lesion is
central to pathogenesis. Colostrum, and in particular, the
sIgA fraction, has been shown previously to inhibit local-
ized adherence of EPEC (21,22). Epidemiologic data also
support the importance of attaching/effacing lesion forma-
tion in the pathogenesis of EHEC. The eaeA gene is more
commonly found in human isolates than bovine EHEC iso-
lates (29,30) and in isolates known to have caused severe
human diseases (31), suggesting that proteins found in
LEE are important virulence factors. 
Previous studies of anti-attaching/effacing antibodies in
human milk (17,19,22,32) have reported data on small
numbers of milk samples, sometimes by using only pooled
colostrum or by using crude antigens. The methodologic
differences between previous studies and the current data
are important to interpretating the data. The most compara-
ble previous study in the literature is that of Parissi-Crivelli
et al. (19). They found antibodies in the colostrum of 21
Mexican women against EspB in 57%, EspA in 76%, and
intimin in 81%, compared with our findings of 44%, 93%,
and 27%, respectively. The differences are important
because the earlier data suggest that intimin is recognized
much more frequently than our results show. Routine recog-
nition of intimin would suggest that mucosal immunity that
occurs naturally during infection targets this antigen. As
such, intimin might be a useful antigen for a potential vac-
cine development plan. However, the difference between
the studies may have occurred because we determined anti-
bodies only to the extracellular C terminal 281-amino acid
portion of intimin gamma that defines tissue tropism (33)
rather than to the whole molecule. Antibodies to the intra-
cellular portion of intimin were not detected by using our
approach. That antibodies to the intracellular portion of
intimin are relevant to protection is biologically implausi-
ble. In fact, antibodies to the N terminal two-thirds of the
intimin molecule do not prevent EHEC from attaching to
HEp2 cells (16). We have therefore focused on antibodies
to the receptor-binding domain (34) that could be relevant
to protection in the gut. This approach makes our observa-
tions more pertinent to intimin gamma-positive EHEC than
to organisms that express other intimin variants.
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Table 2. Comparison of prevalence of secretory immunoglobulin A 
to enterohemorrhagic Escherichia coli antigens in milk samples 




United States (%) 
 (N=50)  p value 
O26  58 (79)  43 (86)  NS
a 
O55  35 (48)  16 (32)  NS 
O111  44 (60)  31 (62)  NS 
O127  42 (58)  19 (38)  NS 
O128  7 (10)  20 (40)  <0.0002 
O157  25 (34)  18 (36)  NS 
Stx  9 (12)  11 (22)  NS 
EspA  68 (93)  45 (90)  NS 
EspB  32 (44)  14 (28)  NS 
Intimin (C281γ)   20 (27)  16 (32)  NS 
aNS, not significant by chi-square
 test. This study supports the previous suggestion that human
milk can be used as an epidemiologic tool (24). Because
lymphocytes travel from the gut to mammary glands by the
common mucosal immune system, sIgA in human milk
reflects previous intestinal infection. Many insights into
antigen-specific sIgA, the most relevant antibody to pro-
tection from intestinal infection, can be gained by studying
human milk. For example, our data show regional varia-
tions in exposure to E. coli LPS types in two study sites.
Exposure to multiple LPS types, including O55 and O111,
correlates with anti-EspA in the United States, while in
Mexico only O55 occurs commonly enough for anti-EspA
to correlate with anti-LPS. The lack of correlation between
the presence of antibodies against Stx1 and O157 LPS in
the United States suggests that mucosal immunity to the
toxin is not related to previous exposure to O157 EHEC. In
Mexico, the primary stimulus for development of antibody
to Stx1 may be becoming infected with O55 or O111
EHEC rather than with O157 EHEC. That these
serogroups are infrequently associated with HUS suggests
that they may be less virulent, less easily diagnosed, or less
likely to cause outbreaks of disease than E. coli O157:H7.
The lack of readily available screening methods for EHEC
serotypes other than O157 may cause the frequency of
non-O157 types to be underestimated. The surprisingly
low frequency of sIgA against Shiga toxin suggests that
mucosal immunity to the toxin is not the basis for the low
frequency of HUS in adults; antibodies with expressed vir-
ulence factors that block attachment are probably more
important. 
We thought that milk samples from the U.S. women
would rarely show evidence of immunity to antigens
expressed by EPEC or EHEC. In fact, the data suggest that
exposure to organisms that produce attaching/effacing
lesions must be much more common than anticipated.
Antibodies to surface antigens of EHEC, particularly those
involved in the initial interaction of bacteria with intestin-
al epithelial cells, frequently are found in human milk. The
data suggest that most women have been exposed to bac-
teria-expressing proteins that mediate the attaching/effac-
ing phenotype, whether these women live in Mexico City
or Norfolk, Virginia. Stool survey data also suggest that
these infections may be occurring more often than com-
monly assumed. Bokete et al. analyzed stools from 445
children in the United States and found that 5.6% shed
non-O157:H7  eaeA+  E. coli (35). A multicenter preva-
lence study on the cause of outpatient pediatric nondysen-
teric diarrhea in the United States showed that 2.7% had E.
coli with localized adherence phenotype or with a positive
probe for EPEC (36). Most U.S. laboratories do not rou-
tinely evaluate pediatric diarrheal stools for the presence of
EPEC or EHEC. The sIgA antibody data shown here, cou-
pled with the stool survey data, suggest that organisms pro-
ducing the attaching/effacing lesion must be common
pathogens in the United States. The similarity between fre-
quencies of antibodies to important surface antigens sug-
gests that the prevalence of HUS in industrialized coun-
tries as opposed to developing countries (37) is not due
solely to differences in frequency of exposure to EPEC.
Our studied showed that EspA was found in most milk
samples (>90%), while Parissi-Crivelli found a much
lower frequency (19). The difference may exist because of
their definition of a positive ELISA for EspA; they arbi-
trarily set an OD >0.2 as positive, while we established a
cutoff by immunoblot. The difference could also reflect the
antigens used for ELISA. We used purified EspA, which
was confirmed by SDS-PAGE to be a single band with no
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Table 3. Comparison of quantity of anti-enterohemorrhagic Escherichia coli secretory immunoglobulin A in milk samples collected from 
women from Mexico and the United States [median and (range) optical density490]
a 
Antigen  Mexico (N=73)  United States (N=50)  p value 
O26  0.143 (0.016–0.305)  0.203 (0.030–0.349)  <0.002 
O55  0.096 (0–0.411)  0.057 (0–0.340)  <0.006 
O111  0.126 (0–0.390)  0.143 (0–0.413)  NS 
O127  0.124 (0–0.416)  0.072 (0–0.350)  <0.004 
O128  0.026 (0–0.228)  0.079 (0.003–0.293)  <0.0000 
O157  0.061 (0–0.470)  0.050 (0–0.260)  NS 
Stx  0.027 (0–0.470)  0.043 (0–0.279)  <0.007 
EspA  0.283 (0.063–0.666)  0.201 (0.015–0.490)  <0.005 
EspB  0.071 (0–0.546)  0.021 (0–0.430)  <0.002 
aMann-Whitney test for differences in amounts of antibodies for the two populations; all samples tested at 1:20 dilution; NS, not significant. 
Table 4. Correlations in amount of antibodies in human milk from 
women in Mexico to various enterohemorrhagic Escherichia coli 
antigens  (correlation/p value) 
Antigen  EspA  EspB  Stx1 
EspB  0.405/<0.001     
Stx1  0.242/NS
a  0.000/NS   
O26  0.161/NS  0.124/NS  0.195/NS 
O55  0.303/<0.01  0.046/NS  0.310/<0.01 
O111  0.235/NS  0.069/NS  0.358/<0.001 
O127  0.164/NS  0.115/NS  0.232/NS 
O128  0.291/NS  0.202/NS  0.002/NS 
O157  0.056/NS  0.133/NS  0.131/NS 
aNS, not significant. detectable contaminants, while Parissi-Crivelli used soni-
cates of organisms expressing an unknown amount of
EspA on a plasmid and subtracted as background the son-
icates of the vector bacteria lacking the gene for EspA. We
studied titers at a 1:20 dilution. Although the relatively low
titers detected could reflect exposure to related antigens
produced by other bacteria, the immunoblots demonstrat-
ed that the antibodies did react with the specific antigens. 
Why the immune system recognizes one antigen more
often than another when both are expressed during infec-
tion is not clear. However, given current understanding of
the virulence mechanism involved in producing attach-
ing/effacing lesions, the secretory IgA data are readily
understandable. The lower frequency of antibodies to
EspB than to anti-EspA reflects that the immune system
has better recognition of the multimeric surface-exposed
EspA organelle. EspB, a protein that is directly injected
into the cytoplasmic membrane of intestinal epithelial cells
through the EspA organelle, is likely to be less available
for uptake by antigen-presenting cells. 
In summary, antibodies against LEE-encoded proteins
were common in samples of human milk from our two
groups. Because of the structural similarity among EspA
variants from multiple pathogens and the high frequency
of anti-EspA antibodies, cross-reactive antibodies against
EspA may provide broad cross-protection against multiple
serotypes. EspA is more conserved than other virulence
antigens; most clone 1 EPEC have identical EspA types,
while most clone 2 are nearly 95% identical (38). EspA in
E. coli O127:H6 and E. coli O157:H7 are 85% identical
(39) EspA is surface expressed and multimeric. Antibody
to EspAis present more often than is antibody to other sur-
face proteins. Natural exposure to EspA appears to elicit a
good immune response that is long lasting as reflected by
the high percentage of women who have anti-EspAin their
milk samples. Unlike antibodies to LPS or intimin (40)
that may protect against a very limited group of
enteropathogens, antibodies to EspA might be able to
block attachment by both EPEC and EHEC of many
serogroups and thereby provide broad cross-protection.
EspAmay be a useful candidate for an immunization strat-
egy that could lead to a vaccine that protects against both
EHEC and EPEC of multiple serotypes.
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